Policy | May 25, 2021
Cipla to market Roche's Antibody Cocktail in India
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
The product patent has been already filed under fast track approval
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
The agreement will help ensure wider reach and access to patients in India
Subscribe To Our Newsletter & Stay Updated
